Baxter(US:BAX) Prnewswireยท2025-10-28 13:38Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [1][3]. Summary by Relevant Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - The firm has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [1]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks to patients [3]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, which led to serious injuries and deaths [3]. - Baxter's attempts to address these defects were deemed inadequate, and the company faced a heightened risk of halting sales of the Novum LVP [3]. Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover not affected by this decision [5]. Additional Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [5].